Design And Development Of Generic Formulation By Applying Reverse Engineering Approach

Main Article Content

Raut R. L.
Chaus W. N.
Kalyankar T. M.
Gattani S. G.


Introduction: The innovator formulation is meat for its high cost as Innovator Company used to invest millions of dollars. The generic formulation is an alternative to beat the cost. The criteria of generic formulation is should have the bioequivalence as that of RLD (Reference Listed Drug). Reverse engineering is decoding of the RLD to find out qualitative and quantitative composition. Rationale behind reverse engineering is if qualitative and quantitative composition of the formulations is same then performance of the formulation will also be same. That helps to speed up the process of generic formulation development and reduces cost and time. The formulation used in study is anti-opioid uni-dose nasal spray 4mg/0.1ml. The formulation contains of anti-opioid drug, benzoalkonium chloride(BKC), EDTA, sodium chloride (NaCl) and pH adjusters like hydrochloric acid, sodium hydroxide.

Objectives: The main objective of current research is to perform reverse engineering of RLD to find out the qualitative and quantitative composition by using different analytical methods and validate the same as per ICH guideline. To develop generic formulation by using data obtained from reverse engineering. To perform similarity matrixing for in-house and RLD formulation.

Methods: Different analytical methods were used to perform the reverse engineering of the RLD to find out the qualitative and quantitative composition like HPLC for benzoalkonium chloride and EDTA. Flame photometry for the NaCl, and the Nano-drop UV for the Anti-opioid drug. The Assay, pH, osmolarity and viscosity were performed for complete characterization of the RLD while for in-house to show the similarity matrixing.

Results: The de-formulation was performed for all the components and the methods were validated as per ICH guideline. The correlation coefficient was >0.99 for all components in all the methods. The recovery results ranged from 99.4 to 99.6% for anti-opioid drug, 99.83−100.33% for BKC, 100.02−100.23% for NaCl and 100.3−100.7% for EDTA. The obtained % RSD for precision study were 0.87% (intraday) and 0.76% (interday) for anti-opioid drug, 0.01% (intraday) and 0.1 (interday) for BKC, 0.62% (intraday) and 0.54 (interday) for NaCl and 0.62%(intraday) and 0.54 (interday) for EDTA. There were no interference of other components and methods are specific.

Conclusions: The reverse engineering gave critical information about the formulation apart from qualitative and quantitative composition like process used by innovator to stabilize the formulation, viscosity of formulation and mechanism of uni-dose nasal spray to provide the better efficacy. That saves time, cost and manpower incurred for the trial batches. The validation of methods gave an assurance for the qualitative and quantitative composition helped for getting affordable bioequivalent generic formulation.

Article Details

How to Cite
Raut R. L., Chaus W. N., Kalyankar T. M., & Gattani S. G. (2023). Design And Development Of Generic Formulation By Applying Reverse Engineering Approach. Journal for ReAttach Therapy and Developmental Diversities, 6(8s), 774–783.
Author Biographies

Raut R. L.

School of Pharmacy S.R.T.M.U. Nanded

Chaus W. N.

Dayanand Institute of Pharmacy Latur

Kalyankar T. M.

School of Pharmacy S.R.T.M.U. Nanded

Gattani S. G.

School of Pharmacy S.R.T.M.U. Nanded


Bansal, A., & Koradia, V. (2005). The role of reverse engineering in the development of generic formulations. Pharmaceutical Technology, 29(8).

Koradia, V. S., Chawla, G., & Bansal, A. K. (2005). Comprehensive characterisation of the innovator product: targeting bioequivalent generics. Journal of Generic Medicines, 2(4), 335-346.

Parasrampuria, s., sertkaya, a., lord, a., & berger, c. (2021). Cost of generic drug development and approval final.

Čapková, T., Pekárek, T., Hanulíková, B., & Matějka, P. (2022). Application of reverse engineering in the field of pharmaceutical tablets using Raman mapping and chemometrics. Journal of Pharmaceutical and Biomedical Analysis, 209, 114496. (accessed: 21 December, 2022). (accessed: 21 December, 2022).

Hasan, M. I., Shimu, S. A., Akther, A., Jahan, I., Hamiduzzaman, M., & Hasan, A. N. (2021). Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review. Journal of Biosciences and Medicines, 9(10), 23-39.

Wermeling, D. P. (2013). A response to the opioid overdose epidemic: naloxone nasal spray. Drug delivery and translational research, 3, 63-74.

McDonald, R., Lorch, U., Woodward, J., Bosse, B., Dooner, H., Mundin, G., ... & Strang, J. (2018). Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. Addiction, 113(3), 484-493.

Guadamuz, J. S., Alexander, G. C., Chaudhri, T., Trotzky-Sirr, R., & Qato, D. M. (2019). Availability and cost of naloxone nasal spray at pharmacies in Philadelphia, Pennsylvania, 2017. JAMA network open, 2(6), e195388-e195388.

Kowtharapu, L. P., Katari, N. K., Sandoval, C. A., Konduru, N., Muchakayala, S. K., Pydimarry, S. P. R., & Jonnalagadda, S. B. (2023). Regulatory Perspective Reverse Engineering Analysis of the Mast Cell Stabilizer and the Histamine Receptor Antagonist (Olopatadine HCl): Instrumental and Classical Methods for Multiple Formulations. ACS omega.

Asch, J., Johnson, K., Mondal, S., & Asch, F. (2022). Comprehensive assessment of extraction methods for plant tissue samples for determining sodium and potassium via flame photometer and chloride via automated flow analysis#. Journal of Plant Nutrition and Soil Science, 185(2), 308-316.

Katata, L., Nagaraju, V., & Crouch, A. M. (2006). Determination of ethylenediaminetetraacetic acid, ethylenediaminedisuccinic acid and iminodisuccinic acid in cosmetic products by capillary electrophoresis and high performance liquid chromatography. Analytica Chimica Acta, 579(2), 177-184.

Tran, G., Chen, C., & Brent Miller, R. (1996). HPLC method for the determination of EDTA in an ophthalmic cleanser. Journal of liquid chromatography & related technologies, 19(9), 1499-1508.

Watrobska–Swietlikowska, D. (2020). Distribution of benzalkonium chloride into the aqueous phases of submicron dispersed systems: emulsions, aqueous lecithin dispersion and nanospheres. AAPS PharmSciTech, 21, 1-10.

Skoog DA, West DM, Holler FJ, Crouch SR. Analytical Chemistry: An Introduction, 7th ed., Chapter 23: 594-631.

García-Alegría, A. M., Anduro-Corona, I., Pérez-Martínez, C. J., Guadalupe Corella-Madueño, M. A., Rascón-Durán, M. L., & Astiazaran-Garcia, H. (2020). Quantification of DNA through the NanoDrop spectrophotometer: methodological validation using standard reference material and Sprague Dawley rat and human DNA. International journal of analytical chemistry, 2020.

Qasim, F. O., Haji, A. A., Qadir, K. M., & Ameen, A. J. M. (2023). Development and Validation of Stability Indicating Nanodrop 2000c UV-Vis Method for Determination of Valsartan in Pharmaceutical formulations. Journal of Pharmaceutical Negative Results, 919-925.

USP 32 – NF 27, General Chapter 1225, Validation of Compendial Methods, 2009.

ICH Q2A, Validation of Analytical Procedures: Definitions and Terminology, Geneva, 1995, in 2005 incorporated in Q2(R1).

Li, B. V., Jin, F., Lee, S. L., Bai, T., Chowdhury, B., Caramenico, H. T., & Conner, D. P. (2013). Bioequivalence for locally acting nasal spray and nasal aerosol products: standard development and generic approval. The AAPS journal, 15, 875-883

Thorat, S. (2016). Formulation and product development of nasal spray: an overview. Scholars journal of applied medical sciences, 4(8D), 2976-2985.

Kulkarni, V., & Shaw, C. (2012). Formulation and characterization of nasal sprays. An examination of nasal spray formulation parameters and excipients and their influence on key in vitro tests. Inhalation, 1015.